Medtrum

Left: a diagram of the Insulet insulin pump patent in question. Top right: The Insulet Omnipod 5. Bottom right: The Medtrum TouchCare Nano.

JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet (Nasdaq: PODD) + in its patent battle with Medtrum.

According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390). The ruling finds that Medtrum’s A6 and A7+ TouchCare insulin pump devices infringe the valid Insulet patent.

However, JUVE-Patent says the judges found that Medtrum’s clinical trials for the A7+ device was responsible for the infringement. The outlet says this is a move “not before seen in French courts.” So, in this instance, Insulet won the patent spat before the infringing devices went commercial. The report says courts usually deliver these types of rulings once products hit the market.

This ruling…

Left: a diagram of the Insulet insulin pump patent in question. Top right: The Insulet Omnipod 5. Bottom right: The Medtrum TouchCare Nano.

According to a report in Europe, a Paris, France, court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent.

JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet.

In declaring the infringement, the court ordered Medtrum to recall its Nano TouchCare pumps sold in France. Patients already using the device received an exemption.

Get the full story at our sister site, Drug Delivery Business News.